Tests that screen seemingly healthy people for many kinds of cancer by analyzing a blood sample are starting to enter the clinic—worrying some physicians and scientists that they could do more harm than good. Last week, NCI advisers endorsed a $75 million, 4-year pilot study enrolling at least 24,000 people to assess the tests, which mostly pick up trace amounts of DNA and proteins that tumors shed into the blood. Some participants will get one of the multicancer blood tests along with standard cancer screening, such as mammograms, whereas a control group will get only the routine tests. Now, as part of President Joe Biden’s reignited Cancer Moonshot, the National Cancer Institute (NCI) is laying plans to evaluate the promise of such tests. What it shows about the feasibility of these tests, sometimes called liquid biopsies, will help NCI decide whether to launch a longer term clinical trial, in as many as 300,000 volunteers ages 45 to 70, to learn whether they save lives. Companies such as GRAIL and Exact Sciences report their tests can detect many tumors at an early stage, when they are easiest to treat. Q: Are there obvious ones to include, like GRAIL’s and Exact Science’s tests? A few tests will then become part of the pilot clinical study beginning in 2023 or 2024. (). Continue reading.
I just stumbled across this old story I told somewhere, and thought I’d share more widely.
Wang announced PyScript as a new framework, built atop one of those earlier projects, to allow Python scripting directly within the browser; those programs have access to much of the existing Python ecosystem as well as being able to interact with the browser document object model (DOM) directly.
The hacker demanded Brooks County pay them $93,000, but county commissioners negotiated with the hacker and eventually agreed to pay less than half that amount.